Badanie Patritumabu Deruxtecanu z innymi lekami przeciwnowotworowymi u pacjentek z rakiem piersi HER2-dodatnim, który się rozprzestrzenił i nie można go usunąć chirurgicznie (MK-1022-009)
HERTHENA-Breast-01: wieloośrodkowe, otwarte badanie fazy 1b/2 mające na celu ustalenie dawki, mające na celu ocenę bezpieczeństwa i działania przeciwnowotworowego patritumabu deruxtecanu u uczestniczek z dodatnim wynikiem HER2, nieresekcyjnym, miejscowo zaawansowanym rakiem piersi lub rakiem piersi z przerzutami
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:
- About the safety and how well people tolerate of patritumab deruxtecan
- How many people have the cancer respond (get smaller or go away) to treatment
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Toll Free Number
- Numer telefonu: 1-888-577-8839
- E-mail: Trialsites@msd.com
Lokalizacje studiów
-
-
-
Haifa, Izrael, 3109601
- Rekrutacyjny
- Rambam Health Care Campus ( Site 0011)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 04-7776234
-
Petah Tikva, Izrael, 4941492
- Rekrutacyjny
- Rabin Medical Center ( Site 0012)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +972-505533121
-
Ramat Gan, Izrael, 5265601
- Rekrutacyjny
- Sheba Medical Center ( Site 0010)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 03-5304498
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japonia, 467-8602
- Rekrutacyjny
- Nagoya City University Hospital ( Site 0020)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +81-52-851-5511
-
-
-
-
Ontario
-
Kingston, Ontario, Kanada, K7L 2V7
- Rekrutacyjny
- Kingston General Hospital ( Site 0061)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 6135336541
-
Toronto, Ontario, Kanada, M5G 2M9
- Rekrutacyjny
- Princess Margaret Cancer Centre ( Site 0001)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 416-946-4501
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrutacyjny
- Jewish General Hospital ( Site 0003)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 514-340-8222
-
Montreal, Quebec, Kanada, H2X 3E4
- Rekrutacyjny
- Centre Hospitalier de l'Université de Montréal ( Site 0004)
-
Kontakt:
- Study Coordinator
- Numer telefonu: (514)890-8000 x20737
-
-
-
-
-
Seoul, Korea Południowa, 03080
- Rekrutacyjny
- Seoul National University Hospital ( Site 0030)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 82-2-2072-0850
-
Seoul, Korea Południowa, 05505
- Rekrutacyjny
- Asan Medical Center ( Site 0031)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +82-2-1688-7575
-
-
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Rekrutacyjny
- University of Colorado Anschutz Medical Campus ( Site 0057)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 720-848-1030
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Rekrutacyjny
- Dana-Farber Cancer Institute ( Site 0050)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 877-338-7425
-
-
New Jersey
-
New Brunswick, New Jersey, Stany Zjednoczone, 08901
- Rekrutacyjny
- Rutgers Cancer Institute of New Jersey ( Site 0052)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 732-235-2465
-
-
South Carolina
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- Rekrutacyjny
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 864-455-3600
-
-
Virginia
-
Fairfax, Virginia, Stany Zjednoczone, 22031
- Rekrutacyjny
- Inova Schar Cancer Institute ( Site 0051)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 571-472-4724
-
-
-
-
Camden
-
London, Camden, Zjednoczone Królestwo, NW1 2PG
- Rekrutacyjny
- University College London Hospital ( Site 0041)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +442034472930
-
-
Glasgow City
-
Glasgow, Glasgow City, Zjednoczone Królestwo, G12 0YN
- Rekrutacyjny
- The Beatson West of Scotland Cancer Centre ( Site 0043)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +441413017000
-
-
London, City of
-
London, London, City of, Zjednoczone Królestwo, EC1A 7BE
- Rekrutacyjny
- St Bartholomew s Hospital ( Site 0040)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +442073777000
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
- Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention
Part 1 Arm 1:
- Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
- Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment
Part 1 Arm 2:
-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
Part 1 Arm 3:
-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.
Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Uncontrolled or significant cardiovascular disease
- Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
- Has clinically severe respiratory compromise
- Has any history of or evidence of any current leptomeningeal disease
- Has clinically significant corneal disease
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
- HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Part 1: Evidence of spinal cord compression or brain metastases
- Part 2: Evidence of spinal cord compression or brain/CNS metastases.
- Has an active infection requiring systemic therapy
- Concurrent active HBV and HCV infection
- Has had major surgical procedure (excluding placement of vascular access) less than 28 days
Part1: Arm 3 ONLY
- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Part 1: Patritumab deruxtecan plus trastuzumab
Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Inne nazwy:
Trastuzumab administered via IV infusion
Inne nazwy:
Trastuzumab biosimilar administered via IV infusion
Inne nazwy:
|
|
Eksperymentalny: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Inne nazwy:
Trastuzumab administered via IV infusion
Inne nazwy:
Trastuzumab biosimilar administered via IV infusion
Inne nazwy:
Pertuzumab administered via IV infusion |
|
Eksperymentalny: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib
Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Inne nazwy:
Trastuzumab administered via IV infusion
Inne nazwy:
Trastuzumab biosimilar administered via IV infusion
Inne nazwy:
Tucatinib administered as oral tablets |
|
Eksperymentalny: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Inne nazwy:
Trastuzumab administered via IV infusion
Inne nazwy:
Trastuzumab biosimilar administered via IV infusion
Inne nazwy:
Pertuzumab administered via IV infusion |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Ramy czasowe: Up to 21 days
|
DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
Ramy czasowe: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Ramy czasowe: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 12 months
|
|
Part 2: Objective Response Rate (ORR)
Ramy czasowe: Up to approximately 36 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented. |
Up to approximately 36 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Ramy czasowe: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Ramy czasowe: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Ramy czasowe: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Ramy czasowe: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Ramy czasowe: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Ramy czasowe: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Ramy czasowe: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Ramy czasowe: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Ramy czasowe: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 2: Duration of Response (DOR)
Ramy czasowe: Up to approximately 36 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Progression Free Survival (PFS)
Ramy czasowe: Up to approximately 36 months
|
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants with One or More AEs
Ramy czasowe: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Ramy czasowe: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 12 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Dyrektor Studium: Medical Director, Merck Sharp & Dohme LLC
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Choroby skórne
- Choroby piersi
- Choroby skóry i tkanki łącznej
- Nowotwory piersi
- Aminokwasy, peptydy i białka
- Białka
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Trastuzumab
- pertuzumab
- Tukatynib
- Patritumab Deruxtecan
- Ogivri
- Ontruzant
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 1022-009
- MK-1022-009 (Inny identyfikator: MSD)
- jRCT2041250022 (Identyfikator rejestru: Japan Registry of Clinical Trials (jRCT))
- 2026-528266-19 (Identyfikator rejestru: EU CT)
- U1111-1346-4321 (Identyfikator rejestru: UTN)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .